Literature DB >> 24698494

Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis.

Katerina Hatzi1, Ari Melnick2.   

Abstract

The B cell lymphoma 6 (BCL6) transcriptional repressor is a master regulator of the germinal center (GC) B cell program, required for their unique proliferative and stress tolerant phenotype. Most B cell lymphomas arise from GC B cells and are dependent on the continued or deregulated expression of BCL6 to maintain their survival. The actions of BCL6 in B cells involve formation of distinct chromatin modifying complexes that silence specific promoter and enhancer networks, respectively. The same biochemical mechanisms are maintained in malignant lymphoma cells. Targeted inhibition of these BCL6 functions has emerged as the basis for rational design of lymphoma therapies and combinatorial regimens. In this review, we summarize recent advances on BCL6 mechanisms of action and the deregulation of its target gene networks in lymphoma.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BCL6; epigenetic regulation; gene enhancers; lymphomagenesis; transcription factor targeted therapy; transcriptional repression

Mesh:

Substances:

Year:  2014        PMID: 24698494      PMCID: PMC4041810          DOI: 10.1016/j.molmed.2014.03.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  73 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

2.  MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation.

Authors:  Naoyuki Fujita; David L Jaye; Cissy Geigerman; Adil Akyildiz; Myesha R Mooney; Jeremy M Boss; Paul A Wade
Journal:  Cell       Date:  2004-10-01       Impact factor: 41.582

3.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

4.  Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.

Authors:  Stella Maris Ranuncolo; Jose M Polo; Jamil Dierov; Michael Singer; Tracy Kuo; John Greally; Roland Green; Martin Carroll; Ari Melnick
Journal:  Nat Immunol       Date:  2007-06-10       Impact factor: 25.606

Review 5.  Germinal-center organization and cellular dynamics.

Authors:  Christopher D C Allen; Takaharu Okada; Jason G Cyster
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

6.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

7.  ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.

Authors:  Nathalie Chevallier; Connie M Corcoran; Christine Lennon; Elizabeth Hyjek; Amy Chadburn; Vivian J Bardwell; Jonathan D Licht; Ari Melnick
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

8.  Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation.

Authors:  Chainarong Tunyaplin; A L Shaffer; Cristina D Angelin-Duclos; Xin Yu; Louis M Staudt; Kathryn L Calame
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

9.  BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.

Authors:  Stella M Ranuncolo; Jose M Polo; Ari Melnick
Journal:  Blood Cells Mol Dis       Date:  2008-03-17       Impact factor: 3.039

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  74 in total

1.  Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.

Authors:  Mingxing Teng; Scott B Ficarro; Hojong Yoon; Jianwei Che; Jing Zhou; Eric S Fischer; Jarrod A Marto; Tinghu Zhang; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2020-04-03       Impact factor: 4.345

Review 2.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

3.  Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region.

Authors:  Karen L Bunting; T David Soong; Rajat Singh; Yanwen Jiang; Wendy Béguelin; David W Poloway; Brandon L Swed; Katerina Hatzi; William Reisacher; Matt Teater; Olivier Elemento; Ari M Melnick
Journal:  Immunity       Date:  2016-09-13       Impact factor: 31.745

4.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.

Authors:  Thibault Dupont; Shao Ning Yang; Jayeshkumar Patel; Katerina Hatzi; Alka Malik; Wayne Tam; Peter Martin; John Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Oncotarget       Date:  2016-01-19

Review 5.  Germinal centres and B cell lymphomagenesis.

Authors:  Katia Basso; Riccardo Dalla-Favera
Journal:  Nat Rev Immunol       Date:  2015-03       Impact factor: 53.106

6.  BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress.

Authors:  Tharu M Fernando; Rossella Marullo; Benet Pera Gresely; Jude M Phillip; Shao Ning Yang; Geoffrey Lundell-Smith; Ingrid Torregroza; Haelee Ahn; Todd Evans; Balázs Győrffy; Gilbert G Privé; Masayuki Hirano; Ari M Melnick; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2019-02-18       Impact factor: 39.397

Review 7.  The emerging complexity of gene fusions in cancer.

Authors:  Fredrik Mertens; Bertil Johansson; Thoas Fioretos; Felix Mitelman
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

8.  Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Jun Qi; Leo Luznik; Ivan Maillard; Kelli P MacDonald; Geoffrey R Hill; Jonathan S Serody; William J Murphy; Peter T Sage; Arlene H Sharpe; David Miklos; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; James E Bradner; Ari M Melnick; Bruce R Blazar
Journal:  Blood       Date:  2018-10-02       Impact factor: 22.113

9.  TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.

Authors:  Pilar M Dominguez; Hussein Ghamlouch; Wojciech Rosikiewicz; Parveen Kumar; Wendy Béguelin; Lorena Fontán; Martín A Rivas; Patrycja Pawlikowska; Marine Armand; Enguerran Mouly; Miguel Torres-Martin; Ashley S Doane; María T Calvo Fernandez; Matt Durant; Veronique Della-Valle; Matt Teater; Luisa Cimmino; Nathalie Droin; Saber Tadros; Samaneh Motanagh; Alan H Shih; Mark A Rubin; Wayne Tam; Iannis Aifantis; Ross L Levine; Olivier Elemento; Giorgio Inghirami; Michael R Green; Maria E Figueroa; Olivier A Bernard; Said Aoufouchi; Sheng Li; Rita Shaknovich; Ari M Melnick
Journal:  Cancer Discov       Date:  2018-10-01       Impact factor: 39.397

10.  BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.

Authors:  Yanhui Cai; Mohamed Abdel-Mohsen; Costin Tomescu; Fengtian Xue; Guoxin Wu; Bonnie J Howell; Yong Ai; Jie Sun; Livio Azzoni; Carole Le Coz; Neil Romberg; Luis J Montaner
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.